Genialis

Genialis

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19M

Overview

Genialis is a Boston-based precision oncology company founded in 2015, focusing on using AI to de-risk and accelerate oncology drug development. Its core technology is the Genialis Supermodel, a foundation AI model of cancer biology, supported by a multiomics data infrastructure called Genialis Expressions. The company provides therapeutic intelligence across the drug development lifecycle, aiming to improve patient stratification, understand drug mechanisms of action, and increase clinical trial success rates for its biopharma partners.

Oncology

Technology Platform

Genialis Supermodel (AI foundation model of cancer biology) and Genialis Expressions (multiomics & clinical data infrastructure).

Funding History

2
Total raised:$19M
Series A$13M
Seed$6M

Opportunities

The high failure rate and cost of oncology clinical trials create a massive market for predictive tools that can improve patient stratification and trial design.
The growing availability of multiomics data provides the fuel for more sophisticated AI models to uncover novel biological insights and biomarkers.

Risk Factors

Key risks include the failure of its AI models to deliver clinically validated predictions, intense competition in the AI-for-drug-discovery space, and the challenges of securing high-quality, diverse datasets necessary for robust model training and regulatory acceptance.

Competitive Landscape

Genialis competes in the crowded AI/ML for drug discovery and precision oncology space, facing competition from pure-play AI biotechs (e.g., Recursion, Exscientia), large tech companies (e.g., Google's Isomorphic Labs), and diagnostic firms building predictive models. Differentiation hinges on the claimed superiority of its 'foundation model' approach and its deep focus on oncology.